Clinical and biomarker changes in dominantly inherited Alzheimer's disease

New England Journal of Medicine

Volumn 367, Issue 9, 2012, Pages 795-804

  Bateman, Randall J ^a   Xiong, Chengjie ^a   Benzinger, Tammie L S ^a   Fagan, Anne M ^a   Goate, Alison ^a   Fox, Nick C ^b   Marcus, Daniel S ^a   Cairns, Nigel J ^a   Xie, Xianyun ^a   Blazey, Tyler M ^a   Holtzman, David M ^a   Santacruz, Anna ^a   Buckles, Virginia ^a   Oliver, Angela ^a   Moulder, Krista ^a   Aisen, Paul S ^c   Ghetti, Bernardino ^d   Klunk, William E ^e   McDade, Eric ^e   Martins, Ralph N ^f   Masters, Colin L ^g   Mayeux, Richard ⁱ   Ringman, John M ^j   Rossor, Martin N ^b   Schofield, Peter R ^h   Sperling, Reisa A ^k   Salloway, Stephen ^l   Morris, John C ^a   more..

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^f EDITH COWAN UNIVERSITY   (Australia)

^g UNIVERSITY OF MELBOURNE   (Australia)

^h UNIVERSITY OF NEW SOUTH WALES   (Australia)

ⁱ University of New South Wales ^*  (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k MASSACHUSETTS GENERAL HOSPITAL   (United States)

^l BROWN UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; AMYLOID PRECURSOR PROTEIN; BIOLOGICAL MARKER; PITTSBURGH COMPOUND B; PRESENILIN 1; PRESENILIN 2; TAU PROTEIN;

ADULT; ALZHEIMER DISEASE; APP GENE; ARTICLE; AUTOSOMAL DOMINANT DISORDER; BRAIN ATROPHY; BRAIN METABOLISM; CLINICAL DEMENTIA RATING SCALE; COGNITIVE DEFECT; CROSS-SECTIONAL STUDY; EPISODIC MEMORY; FEMALE; GENE MUTATION; GLUCOSE METABOLISM; HIPPOCAMPUS; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEMORY DISORDER; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; POSITRON EMISSION TOMOGRAPHY; PRECUNEUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN CEREBROSPINAL FLUID LEVEL; PSEN1 GENE; PSEN2 GENE; RATING SCALE;

EID: 84865529158     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1202753     Document Type: Article

References (33)

1. Brookmeyer R, Evans DA, Hebert L, et al. National estimates of the prevalence of Alzheimer's disease in the United States. Alzheimers Dement 2011;7:61-73.
2. Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol 2010;9:119-28.
3. Price JL, Morris JC. Tangles and plaques in nondemented aging and "preclinical"Alzheimer's disease. Ann Neurol 1999;45:358-68.
4. Braak H, Braak E. Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging 1997;18:351-7.
5. Bapineuzumab in patients with mild to moderate Alzheimer's disease (ApoE4 non-carrier). ClinicalTrials.gov, 2007 (http://clinicaltrials.gov/ct2/show/ NCT00574132).
6. Effect of LY2062430 on the progression of Alzheimer's disease (EXPEDITION). ClinicalTrials.gov, 2009 (http://clinicaltrials.gov/ct2/show/ NCT00905372).
7. Bateman RJ, Aisen PS, De Strooper B, et al. Autosomal-dominant Alzheimer's disease: a review and proposal for the prevention of Alzheimer's disease. Alzheimers Res Ther 2011;3:1.
8. Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science 2002;297:353-6. [Erratum, Science 2002;297:2209.]
9. Merlini G, Bellotti V. Molecular mechanisms of amyloidosis. N Engl J Med 2003; 349:583-96.
10. Summary of opinion (initial authorisation): Vyndaqel. London: European Medicines Agency, 2011 (http://www.ema.europa.eu/ema/index.jsp?curl=pages/ medicines/human/medicines/002294/smops/Positive/human-smop-000246.jsp&mid= WC0b01ac058001d127&murl=menus/medicines/medicines.jsp&jsenabled=true).
11. Johnson SM, Wiseman RL, Sekijima Y, Green NS, Adamski-Werner SL, Kelly JW. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. Acc Chem Res 2005;38:911-21.
12. Perrin RJ, Fagan AM, Holtzman DM. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature 2009;461:916-22.
13. Cruchaga C, Chakraverty S, Mayo K, et al. Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families. PLoS One 2012;7(2):e31039.
14. Lopera F, Ardilla A, Martínez A, et al. Clinical features of early-onset Alzheimer disease in a large kindred with an E280A presenilin-1 mutation. JAMA 1997;277:793-9.
15. Wijsman EM, Daw EW, Yu X, et al. APOE and other loci affect age-at-onset in Alzheimer's disease families with PS2 mutation. Am J Med Genet B Neuropsychiatr Genet 2005;132B:14-20.
16. Morris JC, Ernesto C, Schafer K, et al. Clinical dementia rating training and re- liability in multicenter studies: the Alzheimer's Disease Cooperative Study experience. Neurology 1997;48:1508-10.
17. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state:" a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-98.
18. Wechsler D. WMS-R: Wechsler Memory Scale-Revised: manual. San Antonio, TX: Psychological Corporation, 1987.
19. Mueller SG, Weiner MW, Thal LJ, et al. The Alzheimer's disease neuroimaging initiative. Neuroimaging Clin N Am 2005;15:869-77.
20. Alzheimer Disease & Frontotemporal Dementia Mutation Database home page, 2011 (http://www.molgen.ua.ac.be/ADMutations).
21. Morris JC, Weintraub S, Chui HC, et al. The Uniform Data Set (UDS): clinical and cognitive variables and descriptive data from Alzheimer Disease Centers. Alzheimer Dis Assoc Disord 2006;20:210-6.
22. Jack CR Jr, Petersen RC, Xu YC, et al. Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease. Neurology 1997;49:786-94.
23. Minoshima S, Giordani B, Berent S, Frey KA, Foster NL, Kuhl DE. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Ann Neurol 1997;42:85-94.
24. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential antecedent marker of Alzheimer disease. Neurology 2006;67:446-52.
25. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol 2004;55:306-19.
26. Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in non-demented older adults. Arch Neurol 2007;64:343-9.
27. Ridha BH, Barnes J, Bartlett JW, et al. Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study. Lancet Neurol 2006;5:828-34.
28. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 2007;27:6174-84.
29. Ringman JM, Younkin SG, Pratico D, et al. Biochemical markers in persons with preclinical familial Alzheimer disease. Neurology 2008;71:85-92.
30. Gómez-Isla T, Growdon WB, McNamara MJ, et al. The impact of different presenilin 1 and presenilin 2 mutations on amyloid deposition, neurofibrillary changes and neuronal loss in the familial Alzheimer's disease brain: evidence for other phenotype-modifying factors. Brain 1999;122:1709-19.
31. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7:280-92.
32. Price JL, Ko AI, Wade MJ, Tsou SK, McKeel DW, Morris JC. Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease. Arch Neurol 2001;58:1395-402.
33. Yamamoto A, Sudo H, Endo A. Therapeutic effects of ML-236B in primary hypercholesterolemia. Atherosclerosis 1980;35:259-66.